DOMH vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

DOMH

39.8
AI Score
VS
HIVE Wins

HIVE

64.0
AI Score

Investment Advisor Scores

DOMH

40score
Recommendation
SELL

HIVE

64score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DOMH HIVE Winner
Revenue 68.97M 164.00M HIVE
Net Income -63.96M -221.61M DOMH
Net Margin -92.7% -135.1% DOMH
ROE -277.4% -60.8% HIVE
ROA -114.9% -25.8% HIVE
Total Assets 55.68M 857.69M HIVE
Cash 23.99M 138.99M HIVE

Relative Price Performance (Last 90 Days)

DOMH 1M: -57.4% · 3M: -70.2% HIVE 1M: -25.1% · 3M: -31.2%

Current Technical Phase

DOMH

Markdown
Sell / avoid

Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 19

RSI (14): 18.8 · Price: $0.87

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.6%), weak momentum, RSI 37

RSI (14): 37.1 · Price: $1.78

Fundamentals Snapshot

Metric DOMH HIVE
Market Cap — —
Forward P/E 0.0 -3.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.6% 0.7%
Gross Margin 1.0% 0.4%
Operating Margin -0.1% -0.6%
EPS -5.23 -1.32
Dividend Yield 0.00% —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.